Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

In long-term follow-up of more than 500 patients with melanoma containing a BRAF V600E or V600K mutation, a combination of dabrafenib plus trametinib was associated with progression-free survival in 19% of the patients and overall survival in 34% at 5 years. A complete response to dabrafenib plus tr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-08, Vol.381 (7), p.626-636
Hauptverfasser:	Robert, Caroline, Grob, Jean J, Stroyakovskiy, Daniil, Karaszewska, Boguslawa, Hauschild, Axel, Levchenko, Evgeny, Chiarion Sileni, Vanna, Schachter, Jacob, Garbe, Claus, Bondarenko, Igor, Gogas, Helen, Mandalá, Mario, Haanen, John B.A.G, Lebbé, Celeste, Mackiewicz, Andrzej, Rutkowski, Piotr, Nathan, Paul D, Ribas, Antoni, Davies, Michael A, Flaherty, Keith T, Burgess, Paul, Tan, Monique, Gasal, Eduard, Voi, Maurizio, Schadendorf, Dirk, Long, Georgina V
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Clinical trials Dehydrogenases Female Follow-Up Studies Humans Imidazoles - administration & dosage Imidazoles - adverse effects Inhibitor drugs L-Lactate dehydrogenase Lactic acid Male MAP Kinase Kinase Kinases - antagonists & inhibitors Medical prognosis MEK inhibitors Melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - mortality Melanoma - secondary Metastases Metastasis Middle Aged Multivariate analysis Mutation Oximes - administration & dosage Oximes - adverse effects Patients Progression-Free Survival Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Pyridones - administration & dosage Pyridones - adverse effects Pyrimidinones - administration & dosage Pyrimidinones - adverse effects Response rates Skin Neoplasms - drug therapy Skin Neoplasms - mortality Skin Neoplasms - pathology Survival Survival Rate Targeted cancer therapy Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In long-term follow-up of more than 500 patients with melanoma containing a BRAF V600E or V600K mutation, a combination of dabrafenib plus trametinib was associated with progression-free survival in 19% of the patients and overall survival in 34% at 5 years. A complete response to dabrafenib plus trametinib was the strongest predictor of long-term survival.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1904059